MAB8251
Anti-Influenza A Antibody, nucleoprotein, clones A1, A3 Blend
ascites fluid, Chemicon®, from mouse
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
ascites fluid
antibody product type
primary antibodies
clone
A1, monoclonal
A3, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable
isotype
IgG1 (A3)
IgG2a (A1)
shipped in
wet ice
Specificity
All subtypes of Influenza A (H1N1, H2N2 and H3N2 and H5N1). Specific for the nucleoprotein antigen. No cross-reactivity seen to Influenza B, Parainfluenza 1, 2 or Adenovirus or RSV.
Immunogen
Influenza A blend.
Application
Indirect immunofluorescence at 1:100-1:1000.
Optimal working dilutions must be determined by end user.
Optimal working dilutions must be determined by end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
This Anti-Influenza A Antibody, nucleoprotein, clones A1, A3 Blend is validated for use in IF for the detection of Influenza A.
Physical form
Ascites fluid containing no preservatives.
Unpurified
Storage and Stability
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Analysis Note
Control
Influenza Control Slides, Catalogue Number 5010-5
Influenza Control Slides, Catalogue Number 5010-5
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class
10 - Combustible liquids
wgk_germany
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Validation of a method for preparing influenza H5N1 simulated samples.
John A Lednicky,Julie M Villanueva,Stephen A Burke,Roxanne Shively,Michael W Shaw et al.
Journal of Virological Methods null
Rui Jia et al.
Cellular microbiology, 16(7), 1080-1093 (2014-02-14)
Members of the interferon-induced transmembrane (IFITM) protein family inhibit the entry of a wide range of viruses. Viruses often exploit the endocytosis pathways to invade host cells and escape from the endocytic vesicles often in response to low pH. Localization
Nara Lee et al.
Nucleic acids research, 45(15), 8968-8977 (2017-09-16)
Influenza A virus (IAV) genomes are composed of eight single-stranded RNA segments that are coated by viral nucleoprotein (NP) molecules. Classically, the interaction between NP and viral RNA (vRNA) is depicted as a uniform pattern of 'beads on a string'.
Shuguang Han et al.
Clinical and experimental pharmacology & physiology, 45(1), 84-93 (2017-08-31)
Curcumin, an active phenolic agent extract from the Curcuma longa, exhibits excellent anti-cancer, anti-inflammation, and neuroprotective effects. We aimed to investigate the anti-influenza role of curcumin in vitro and in vivo. The effect of curcumin on replication of influenza A
Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus.
McCullers, JA; Van De Velde, LA; Allison, KJ; Branum, KC; Webby, RJ; Flynn, PM
Clinical Infectious Diseases null
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service